Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2023 07:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
March 27, 2023 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
March 06, 2023 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa

- Study Did Not Meet Primary or Secondary Efficacy Endpoints in Hidradenitis Suppurativa- Overall Safety Profile and PK/PD Generally Consistent with Observations in Prior Studies of Zunsemetinib ...
February 23, 2023 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

WAYNE, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
February 09, 2023 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
January 06, 2023 07:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Provides 2023 Outlook

WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
November 29, 2022 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates...
November 22, 2022 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Key Leadership Transitions

- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr....
November 10, 2022 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences

WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
November 08, 2022 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

- Completed Enrollment in Phase 2a Trial of Zunsemetinib in Hidradenitis Suppurativa; Topline Data Expected in Mid-first Half of 2023 - Announced Patent License Agreement with Lilly for the Treatment...